Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patient Receiving Radiotherapy for Nasopharyngeal Carcinoma
NCT06017895Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Oct 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of doxepin in 19p13.3 microduplication syndrome (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Reduction of swallowing-induced pain at 60 minutes. Started Oct 2023; status: recruiting.
02
Drugs
doxepin
03
Conditions
19p13.3 microduplication syndrome
Beyond the preview
Go deeper on NCT06017895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06017895.